Teva Pharmaceuticals

Pipeline, portfolio, pace… see what our strategy looks like in motion. On July 29, join President and CEO Richard Francis and the Teva leadership team for our Q2 2026 earnings call. 📅 Wednesday, July 29, 8:00 AM ET | 2:00 PM CET | 3:00 PM IL 🔗 Webcast: https://ow.ly/1LNz50ZrfNk Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release.

An exciting moment for Teva 📢 The Lancet Gastroenterology & Hepatology published the latest analyses from our Phase 2b study evaluating an investigational treatment for #UlcerativeColitis (UC) and #CrohnsDisease (CD). These peer-reviewed data mark an important milestone for our innovative medicines pipeline and, most importantly, for those living with UC and CD. Many thanks to the investigators, researchers, and study participants, who helped make this publication possible. Vipul Jairath Walter Reinisch Read more: https://lnkd.in/eHtUn9ts https://lnkd.in/eSKX_srw #InflammatoryBowelDisease #TevaPharm

“I'll never forget how, during a time when I believed I had no shelter from my own internal destruction, a stranger created a sanctuary for me.” Diagnosed with schizophrenia and recovering from a severe psychotic episode, Matt believed he’d finally found his calling: becoming a clinical social worker. Finding a way to help others didn't just feel meaningful; it felt essential. However, the voice of self-doubt didn't make things easy. It kept asking, “Is this really what you want – or is it a desperate attempt to find purpose?” Today, Matt shares the two pivotal moments that became his “whys” for pursuing a career in counseling. Read his full story here: https://ow.ly/7Pyz50Zoik6

תודה לך Inbar Shenfeld על מפגש חשוב ופורה! https://lnkd.in/dPvsnGEw

Vitiligo is often misunderstood, but it is not a cosmetic condition. It's a chronic autoimmune disorder that affects millions of people worldwide, and can affect emotional wellbeing, confidence, and quality of life. Here is Patricia Frausto-Rodriguez sharing the realities behind what you can (and can't) see. Explore more about vitiligo and the experiences behind it: https://ow.ly/v91U50Zm356

Today, Teva and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both intravenous and subcutaneous formulations of Polpharma Biologics’ biosimilar candidate for multiple sclerosis, upon regulatory approval.   This strategic partnership combines Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities, reflecting both companies' shared commitment to broadening access to biologic medicines while promoting the long-term sustainability of healthcare systems.   “This agreement is aligned with Teva’s Pivot to Growth strategy and our focus on expanding our biosimilars pipeline. With our global commercial footprint and deep expertise in complex medicines, we are well positioned to help bring this biosimilar candidate to patients,” said Yolanda Tibbe, Vice President, Global Head of Biosimilars at Teva.   Learn more: https://lnkd.in/eVQU77wa   #PivotToGrowth #Biosimilars #MultipleSclerosis

Vitiligo can affect far more than the skin. This chronic autoimmune disease, which causes loss of pigmentation, often carries a significant impact on a person’s quality of life, self-image, and daily social interactions. And despite recent advances, treatment options remain limited. Today, we announced plans to advance TEV-’408, our investigational human monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo. “TEV-’408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline,” said Richard Francis, President and Chief Executive Officer of Teva. “Grounded in compelling biology and focused on meaningful unmet need, TEV-’408 reflects our progress in our Pivot to Growth strategy and our commitment to pursuing differentiated innovation for patients.” To learn more, join the webcast today at 8:00 AM EST: https://lnkd.in/e5ZZYY3T Read the full press release: https://bit.ly/4ynYagW

Every career move is a step toward something new: a fresh challenge, a different environment, or an opportunity to grow. What matters most to you? Vote below, and share your answer in the comments if it isn’t listed.

"I define emotional recovery as trusting and believing in yourself again and wanting to be you. Focusing on this gives you the confidence, motivation and patience to persist and do the hard work it takes to recover. We need to create more dialogue about how we're feeling and how our mental health is." What if we answered honestly when someone asked how we were doing? Sarah Merritt Ryan - writer, speaker, and advocate living in full remission from schizophrenia - knows what it costs to pretend you're fine when you aren't. She also knows what it feels like to stop pretending. Emotional recovery is about reclaiming your voice, being honest about how you actually are, and refusing to suffer in silent shame. That takes courage. And it takes a culture that makes it safe to tell the truth - in clinics, in workplaces, in communities. Read more from Sarah: https://ow.ly/MTqN50ZjCrc #MentalHealthAwareness #EmotionalRecovery #EndStigma #SchizophreniaAwareness

In ten years, healthcare will look radically different. This was the thought-provoking premise posed by Dr. Daniel Kraft, MD – a global expert at the intersection of healthcare, AI, and innovation and the founder of NextMed Health – in a session with our leadership team and internal innovators, as part of the Teva Rise Innovation Leadership Program. Healthcare is entering a period of rapid transformation, where innovation is expected to move from concept to real-world impact at speed. This transition calls for trusted, strong leadership to guide organizations through complexity and change, leadership that can align science, data, and patient insight in a coherent direction, while staying grounded in clarity, responsibility, and purpose. We see this moment as a defining shift for biopharma, a call to actively shape what comes next, to continuously reinvent from within, and to bring innovation closer to patients in ways that truly matter.